A Randomized, Double-blind, Placebo-controlled Multicenter Phase II/III Study to Evaluate the Efficacy and Safety of Tegaserod and Placebo Given Orally for 12 Weeks for the Treatment of Opioid-induced Constipation (OIC) in Patients with Chronic Non-Cancer04/10/2006 - 07/10/2008 (PI)
Novartis Pharmaceuticals Corporation
The Impact of Patient Education on Clinical Outcomes in Irritable Bowel Syndrome07/01/2006 - 06/30/2009 (PI)
American College of Gastroenterology
Survey in Patient Education of IBS09/01/2004 - 08/31/2007 (PI)
GlaxoSmithKline